FDA approved human growth hormone

, , ,

On Oct. 18, 1985, Genentech received U.S. Food and Drug Administration (FDA) approval of its first medicine, Protropin (somatrem for injection), the second genetically engineered drug and the first recombinant pharmaceutical product to be sold by Genentech.

In the early 1970s, biochemist Herb Boyer and geneticist Stanley Cohen pioneered a new scientific field called recombinant DNA technology. Upon learning about the technology, venture capitalist Bob Swanson placed a call to Boyer and requested a meeting. By the meeting’s conclusion, Genentech was born, and Boyer and Swanson went on to found the company in 1976.

Although Swanson and Boyer faced skepticism from both the academic and business communities, they forged ahead with their idea to develop a new generation of therapeutics created from genetically engineered copies of naturally occurring molecules important in human health and disease. Within a few short years, Genentech scientists proved it was possible to make medicines by splicing genes into fast-growing bacteria that produced therapeutic proteins.

Tags:


Source: Genentech
Credit:

Advertise in our E-history sent to 5,000 plus company decision makers twice per month for only $300 per month. Reserve your space now! E-mail: info@LifeScienceHistory.com.